Physician profile
Michael C Saavedra
NPI 1497946685
$9,819.18
in general payments reported to CMS, 2019-2025
24 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $453 · 2020: $312 · 2021: $564 · 2022: $2,001 · 2023: $3,074 · 2024: $1,982 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,409 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,408.65 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,864.33 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,845.53 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $810.15 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $674.27 | 2019-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $614.47 | 2019-2025 | |
| Genentech USA, INC. | $537.31 | 2019-2025 | Xolair |
| Amgen INC. | $517.18 | 2022-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $385.29 | 2020-2024 | Cuvitru, Takhzyro |
| Kaleo, INC. | $213.20 | 2021-2023 | Auvi-Q |
| Optinose US, INC. | $207.74 | 2020-2024 | |
| Biocryst US Sales Co., LLC | $179.35 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $166.01 | 2023-2025 | Ruconest |
| Csl Behring | $148.51 | 2019-2025 | Andembry, Hizentra |
| Alk-Abello, INC | $117.75 | 2022-2023 | Grastek, Odactra, Ragwitek |
| Grifols USA, LLC | $110.97 | 2021-2025 | Xembify |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $66.82 | 2020-2021 | |
| Pfizer INC. | $64.19 | 2020-2025 | |
| Shire North American Group INC | $52.60 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.18 | 2019-2022 | |
| Greer Laboratories, INC. | $40.07 | 2022-2023 | Oralair |
| Inspire Medical Systems, INC. | $30.15 | 2025 | Inspire |
| Adma Biomanufacturing LLC | $26.80 | 2022 | |
| Hikma Pharmaceuticals USA | $18.32 | 2024 | Ryaltris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Saavedra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.